Pacific Biosciences of California Gestione

Gestione criteri di controllo 2/4

Pacific Biosciences of California Il CEO è Christian O. Henry, nominato in Sep2020, e ha un mandato di 4.17 anni. la retribuzione annua totale è $ 8.05M, composta da 8.6% di stipendio e 91.4% di bonus, comprese azioni e opzioni aziendali. possiede direttamente 0.14% delle azioni della società, per un valore di € 671.50K. La durata media del mandato del team dirigenziale e del consiglio di amministrazione è rispettivamente 4.2 anni e 11.8 anni.

Informazioni chiave

Christian O. Henry

Amministratore delegato

US$8.0m

Compenso totale

Percentuale dello stipendio del CEO	8.6%
Mandato del CEO	4.2yrs
Proprietà del CEO	0.1%
Durata media del management	4.2yrs
Durata media del Consiglio di amministrazione	11.8yrs

Aggiornamenti recenti sulla gestione

Recent updates

Analisi delle retribuzioni degli amministratori delegati

Come è cambiata la remunerazione di Christian O. Henry rispetto agli utili di Pacific Biosciences of California?
Data	Compenso totale	Stipendio	Guadagni aziendali
Sep 30 2024	n/a	n/a	-US$394m
Jun 30 2024	n/a	n/a	-US$400m
Mar 31 2024	n/a	n/a	-US$297m
Dec 31 2023	US$8m	US$695k	-US$307m
Sep 30 2023	n/a	n/a	-US$309m
Jun 30 2023	n/a	n/a	-US$319m
Mar 31 2023	n/a	n/a	-US$321m
Dec 31 2022	US$7m	US$667k	-US$314m
Sep 30 2022	n/a	n/a	-US$299m
Jun 30 2022	n/a	n/a	-US$206m
Mar 31 2022	n/a	n/a	-US$175m
Dec 31 2021	US$3m	US$650k	-US$181m
Sep 30 2021	n/a	n/a	-US$37m
Jun 30 2021	n/a	n/a	-US$77m
Mar 31 2021	n/a	n/a	-US$59m
Dec 31 2020	US$13m	US$195k	US$29m
Sep 30 2020	n/a	n/a	-US$46m
Jun 30 2020	n/a	n/a	-US$51m
Mar 31 2020	n/a	n/a	-US$53m
Dec 31 2019	US$100k	n/a	-US$84m
Sep 30 2019	n/a	n/a	-US$115m
Jun 30 2019	n/a	n/a	-US$111m
Mar 31 2019	n/a	n/a	-US$109m
Dec 31 2018	US$88k	n/a	-US$103m

Compensazione vs Mercato: La retribuzione totale di Christian O. ($USD 8.05M ) è superiore alla media delle aziende di dimensioni simili nel mercato German ($USD 1.03M ).

Compensazione vs guadagni: La retribuzione di Christian O. è aumentata nonostante l'azienda non sia redditizia.

AMMINISTRATORE DELEGATO

Christian O. Henry (56 yo)

4.2yrs

Mandato

US$8,046,575

Compensazione

Mr. Christian O. Henry, MBA, served as Independent Director at CM Life Sciences III Inc. since April 07, 2021 until December 2021. He has been President and Chief Executive Officer at Pacific Biosciences o...

Gruppo dirigente

Nome	Posizione	Mandato	Compensazione	Proprietà
Christian O. Henry	President	4.2yrs	US$8.05m	0.14% € 671.5k
Susan Kim	Chief Financial Officer	4.2yrs	US$2.52m	0.043% € 204.4k
Mark Van Oene	Chief Operating Officer	3.8yrs	US$4.60m	0.12% € 546.9k
Stephen Turner	Co-Founder	24.3yrs	US$466.76k	Nessun dato
Michele Farmer	VP & Chief Accounting Officer	3.5yrs	Nessun dato	0.013% € 62.6k
Brett Atkins	General Counsel & Corporate Secretary	no data	Nessun dato	Nessun dato
Natalie Welch	Chief People Officer	no data	Nessun dato	Nessun dato

4.2yrs

Durata media

51yo

Età media

Gestione esperta: Il team dirigenziale di P09 è considerato esperto (durata media dell'incarico 4.2 anni).

Membri del Consiglio di amministrazione

Nome	Posizione	Mandato	Compensazione	Proprietà
Christian O. Henry	President	6.3yrs	US$8.05m	0.14% € 671.5k
William Ericson	Independent Director	20.8yrs	US$259.00k	0.0069% € 32.5k
Lucy Shapiro	Independent Director	12.2yrs	US$255.00k	0% € 0
John Milligan	Independent Chairman	11.3yrs	US$297.00k	0.040% € 190.2k
Harry Gray	Member of the Scientific Advisory Board	no data	Nessun dato	Nessun dato
Joseph Bonventre	Member of the Scientific Advisory Board	no data	Nessun dato	Nessun dato
Randall Livingston	Independent Director	15.8yrs	US$265.00k	0% € 0
Harold Craighead	Member of the Scientific Advisory Board	no data	Nessun dato	Nessun dato
Roger Kornberg	Member of the Scientific Advisory Board	no data	Nessun dato	Nessun dato
Watt Webb	Member of the Scientific Advisory Board	no data	Nessun dato	Nessun dato
Kenneth Johnson	Member of the Scientific Advisory Board	no data	Nessun dato	Nessun dato
Jay Shendure	Chairman of Scientific Advisory Board	2yrs	Nessun dato	Nessun dato

11.8yrs

Durata media

70yo

Età media

Consiglio di amministrazione esperto: Il consiglio di amministrazione di P09 è composto da personale esperto e esperto (durata media dell'incarico 11.8 anni).

Pacific Biosciences of California Gestione

Gestione criteri di controllo 2/4

Informazioni chiave

Aggiornamenti recenti sulla gestione

President recently sold €155k worth of stock

Chief Operating Officer recently sold €57k worth of stock

Pacific Biosciences of California, Inc., Annual General Meeting, Jun 18, 2024

Insider recently bought €162k worth of stock

President recently sold €445k worth of stock

Chief Operating Officer recently sold €221k worth of stock

Recent updates

New minor risk - Shareholder dilution

Third quarter 2024 earnings released: US$0.22 loss per share (vs US$0.26 loss in 3Q 2023)

PacBio Unveils the Vega System

PacBio Announces SPRQ Chemistry for Revio Sequencing Systems

Pacific Biosciences of California, Inc. to Report Q3, 2024 Results on Nov 07, 2024

President recently sold €155k worth of stock

Chief Operating Officer recently sold €57k worth of stock

Pacific Biosciences of California, Inc. Reports Goodwill Impairment for the Second Quarter Ended June 30, 2024

Pacific Biosciences of California, Inc. to Report Q2, 2024 Results on Aug 07, 2024

Pacific Biosciences of California, Inc.(NasdaqGS:PACB) dropped from Russell 2500 Growth Index

First quarter 2024 earnings released: US$0.29 loss per share (vs US$0.36 loss in 1Q 2023)

Pacific Biosciences of California, Inc., Annual General Meeting, Jun 18, 2024

Pacific Biosciences of California, Inc. Provides Revenue Guidance for the Second Quarter and Full Year 2024

PacBio Announces PureTarget Repeat Expansion Panel, Expanding Its Portfolio of End-To-End Clinical Research Solutions

Insider recently bought €162k worth of stock

Full year 2023 earnings released: US$1.21 loss per share (vs US$1.40 loss in FY 2022)

President recently sold €445k worth of stock

Full year 2023 earnings released: US$1.21 loss per share (vs US$1.40 loss in FY 2022)

Pacific Biosciences of California, Inc Announces HiFi Prep Kit 96 and HiFi Plex Prep Kit 96 for Long-Read Sequencing Applications at Scale

Pacific Biosciences of California, Inc. to Report Q4, 2023 Results on Feb 15, 2024

PacBio Announces New Nanobind Pandna Kit Enabling Hifi Optimized Dna Extraction Solutions

Chief Operating Officer recently sold €221k worth of stock

Pacific Biosciences of California, Inc. Announces Resignation of David Botstein from the Board

PacBio Announces HiFi Solves, a Global Consortium of Clinical Genomics Research Leaders

Third quarter 2023 earnings released: US$0.26 loss per share (vs US$0.34 loss in 3Q 2022)

Pacific Biosciences of California, Inc. Appoints David Meline to Audit Committee

Pacific Biosciences of California, Inc. Appoints David Meline to its Board of Directors

Pacific Biosciences of California, Inc. to Report Q3, 2023 Results on Oct 30, 2023

Pacbio Announces Complete Computational Workflow for Human Whole Genome Sequencing Data Analysis

President recently sold €918k worth of stock

Chief Operating Officer recently sold €263k worth of stock

Pacific Biosciences of California, Inc. (NasdaqGS:PACB) entered into an agreement to acquire Apton Biosystems, Inc. for approximately $110 million.

Second quarter 2023 earnings released: US$0.28 loss per share (vs US$0.32 loss in 2Q 2022)

Pacific Biosciences of California, Inc. (NasdaqGS:PACB) entered into an agreement to acquire Apton Biosystems, Inc. for $110 million.

Pacific Biosciences of California, Inc. to Report Q2, 2023 Results on Aug 02, 2023

Now 25% undervalued

Pacific Biosciences of California, Inc. Announces Board Changes

VP & Chief Accounting Officer recently sold €60k worth of stock

Insufficient new directors

Full year 2022 earnings released: US$1.40 loss per share (vs US$0.89 loss in FY 2021)

PacBio to Expand MAS-Seq Technology to 16S rRNA and Bulk RNA-Seq Solutions

Pacific Biosciences of California, Inc. to Report Q4, 2022 Results on Feb 16, 2023

Insufficient new directors

Pacific Biosciences of California, Inc. has completed a Follow-on Equity Offering in the amount of $175 million.

Pacific Biosciences of California, Inc. has completed a Follow-on Equity Offering in the amount of $175 million.

Pacific Biosciences of California, Inc. Provides Revenue Guidance for Fourth Quarter and Full Year 2022

Pacific Biosciences of California, Inc. Announces Board Appointments

Pacific Biosciences of California, Inc. Withdraws its Financial Guidance

Pacific Biosciences of California, Inc. to Report Q3, 2022 Results on Nov 07, 2022

PacBio Launches Single-Cell Transcriptome Solution Ushering in a New Era of RNA Discovery

PacBio and Twist Bioscience Deliver Initial Portfolio of Target Enrichment Panels for HiFi Sequencing

Chief Financial Officer recently sold €75k worth of stock

PacBio Unveils A New Method for Comprehensive, Genome-Wide Tandem Repeat Analysis

Second quarter 2022 earnings released: US$0.32 loss per share (vs US$0.21 loss in 2Q 2021)

Pacific Biosciences of California, Inc. Provides Revenue Guidance for the Full Year 2022

Pacific Biosciences of California, Inc. Appoints Jeff Eidel as Chief Commercial Officer, Effective August 16, 2022

Pacific Biosciences of California, Inc. to Report Q2, 2022 Results on Aug 03, 2022

Pacific Biosciences of California, Inc. Announces Management Changes

First quarter 2022 earnings released: US$0.37 loss per share (vs US$0.45 loss in 1Q 2021)

Insufficient new directors

Pacific Biosciences of California, Inc. to Report Q1, 2022 Results on May 04, 2022

Pacific Biosciences of California, Inc., Annual General Meeting, May 25, 2022

Insufficient new directors

Full year 2021 earnings: Revenues and EPS in line with analyst expectations

Pacific Biosciences of California, Inc. to Report Q4, 2021 Results on Feb 15, 2022

Chief Operating Officer recently sold €519k worth of stock

Pacific Biosciences of California, Inc. Provides Revenue Guidance for the Fourth Quarter and the Fiscal Year Ended December 31, 2021

PacBio’s New HiFiViral Surveillance Kit Performance is Not Impacted by Omicron Mutations, Delivering Complete SARS-CoV-2 Genomes for All Circulating Variants

Insufficient new directors